Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.50 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783028 | 0.76 | CA1 (0.67) | CYP26A1MTNR1BMTNR1AHTR2CDRD2 | |
| SCHEMBL7280376 | 0.76 | MTNR1A (0.52) | MTNR1BMTNR1ACYP19A1NQO2 | |
| SCHEMBL6401395 | 0.74 | CYP19A1 (0.49) | MTNR1BMTNR1AHTR2CCYP19A1SMN1; SMN2 | |
| SCHEMBL7272139 | 0.74 | LMNA (0.58) | MTNR1BMTNR1AHTR2CCYP19A1HTR2B | |
| SCHEMBL6401397 | 0.74 | CYP19A1 (0.49) | MTNR1BMTNR1AHTR2CCYP19A1SMN1; SMN2 | |
| SCHEMBL8921371 | 0.74 | CYP24A1 (0.54) | CYP24A1CYP27A1CYP26A1MTNR1BMTNR1A | |
| SCHEMBL9855296 | 0.73 | CYP24A1 (0.63) | CYP24A1CYP27A1CYP26A1MTNR1ACYP19A1 | |
| SCHEMBL630276 | 0.73 | CYP24A1 (0.70) | CYP24A1CYP27A1CYP26A1HTR2CCYP19A1 | |
| SCHEMBL13039619 | 0.72 | DRD2 (0.60) | CYP24A1CYP27A1CYP26A1HTR2CCYP19A1 | |
| SCHEMBL972021 | 0.72 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP26A1HTR2CCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053108-B2 | Indoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-30 | — | — | US | disclosed |
| US-6998403-B2 | Benzoindoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-02-14 | — | — | US | disclosed |
| EP-1516871-A1 | Benzoindoline derivatives with adrenergic activity | Les Laboratoires Servier (FR) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | LES LABORATOIRES SERVIER (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040192736-A1 | New indoline compounds | LAVIELLE GILBERT (FR) | 2004-09-30 | — | — | US | disclosed |
| US-6759421-B2 | N-(3-PYRIDYL)-1,2-DIHYDRO-3H-BENZO(E)INDOLE-3-CARBOXAMIDE DERIVATIVES USEFUL AS A 5-HT2C ANTAGONIST | LES LABORATOIRES SERVIER (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1348704-A1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | TPH1, IDO1, HTR3A | CYP24A1 1625/4885CYP27A1 2027/4885CYP26A1 887/4885 |
| US-20040192736-A1 | New indoline compounds | TPH1, HTR3A, HTR1D | CYP24A1 2402/4885CYP27A1 2476/4885CYP26A1 1219/4885 |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | HTR2C, HTR2A, ADRA2C | CYP24A1 1547/4885CYP27A1 2015/4885CYP26A1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.